US Stock Insider Trading | Heartflow disclosed two insider transactions on February 6

K-LinePoet · 2026-02-07T04:05:38+00:00

Heartflow disclosed internal trading information on February 6, 2026. Major shareholder Bain Capital sold 2 million shares, and directors and executives also engaged in related transactions. The company utilizes AI and software to develop non-invasive solutions for diagnosing coronary artery disease.

K-LinePoet

2026-02-07 04:05:38

Abstract generation in progress

On February 6, 2026, Heartflow (HTFL) disclosed two insider trading transactions. Shareholder Bain Capital Life Sciences Investors, LLC, holding more than 10% of shares, sold 2,000,000 shares on February 5, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Shareholder with over 10%	Bain Capital Life Sciences Investors, LLC	February 4, 2026	Sell	2,000,000	28.05	56.1 million
February 6, 2026	Director	Cullivan Julie A	February 5, 2026	Sell	8,000	27.32	218,600
December 17, 2025	Director	Lightcap Jeffrey C	December 16, 2025	Buy	40,000	26.34	1.0537 million
November 12, 2025	Director	Farquhar John C.M.	November 7, 2025	Sell	1,339	32.56	43,600
November 12, 2025	Executive	Rogers Campbell	November 7, 2025	Sell	439	32.56	14,300
November 12, 2025	Executive	Jones Marie L.	November 7, 2025	Sell	81	32.56	2,637.36
November 12, 2025	Executive	Verghese Vikram	November 7, 2025	Sell	471	32.56	15,300

【Company Information】

Heartflow, Inc. was incorporated in 2007 under Delaware law. Heartflow pioneered the use of software and artificial intelligence to provide a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease, which is a leading cause of death worldwide. Their new platform leverages artificial intelligence and advanced computational fluid dynamics to create personalized 3D models of patients’ hearts from a single coronary computed tomography angiography (CTA) scan, a specialized imaging type that provides detailed images of the heart arteries. Their Heartflow platform offers insights into blood flow, stenosis, plaque volume, and composition, overcoming the limitations of traditional non-invasive imaging tests that rely on indirect measurements of coronary artery disease, which can lead to higher false-negative and false-positive rates, as demonstrated by their precise trials.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.